摘要
Cysteine is an amino acid necessary for the synthesis of all proteins, the antioxidant glutathione, and the neuromodulator taurine. Whether cysteine is an essential amino acid for premature neonates remains controversial. Using a [13C6]glucose precursor in very-low-birth weight (VLBW) premature neonates, we measured the 13C content of cysteine in hepatically derived apolipoprotein (apo) B-100 and in the plasma to determine whether cysteine synthesis occurs and to relate minimum synthetic capacity to neonatal maturity. Twelve VLBW premature neonates (birth weight, 907 ±274 [SD] g; gestational age, 26.8 ±2.4 weeks) were studied on day of life 7.8 ±4.2 while on total parenteral nutrition (TPN) for 5.6 ±4.5 days. A 4-hour intravenous infusion of [13C6]glucose was administered. Blood samples were obtained immediately before and at the end of the infusion. Isotopic enrichment of cysteine was determined by gas chromatography/mass spectrometry. Analysis of variance, Student’s t test, and linear regression were used for comparisons. The 13C isotope ratio of apo B-100-derived cysteine after the [13C6]glucose infusion was significantly higher than baseline (18.57 ±0.38 [SEM] vs 17.54 ±0.25 mol%, P < .05). The 13C isotope ratio of plasma cysteine was also significantly higher than baseline (17.36 ±0.25 vs 16.91 ±0.16 mol%, P < .05)-. When expressed as a product/precursor ratio, the mole percent above baseline of [13C]apo B-100 cysteine/ [13C6]-glucose correlated with birth weight (r = 0.74, P < .01). Very low-birth weight neonates are capable of cysteine synthesis as evidenced by incorporation of 13C label into hepatically derived apo B-100 cysteine and plasma cysteine from a glucose precursor. The minimum capacity for intrahepatic cysteine synthesis appears to be directly proportional to the maturity of the neonate and may impact the capabilities of VLBW neonates to counteract oxidative stresses such as bronchopulmonary dysplasia and necrotizing enterocolitis.
Cysteine is an amino acid necessary for the synthesis of all proteins, the antioxidant glutathione, and the neuromodulator taurine. Whether cysteine is an essential amino acid for premature neonates remains controversial. Using a [13C6]glucose precursor in very-low-birth weight (VLBW) premature neonates, we measured the 13C content of cysteine in hepatically derived apolipoprotein (apo) B-100 and in the plasma to determine whether cysteine synthesis occurs and to relate minimum synthetic capacity to neonatal maturity. Twelve VLBW premature neonates (birth weight, 907 ±274 [SD] g; gestational age, 26.8 ±2.4 weeks) were studied on day of life 7.8 ±4.2 while on total parenteral nutrition (TPN) for 5.6 ±4.5 days. A 4-hour intravenous infusion of [13C6]glucose was administered. Blood samples were obtained immediately before and at the end of the infusion. Isotopic enrichment of cysteine was determined by gas chromatography/mass spectrometry. Analysis of variance, Student’s t test, and linear regression were used for comparisons. The 13C isotope ratio of apo B-100-derived cysteine after the [13C6]glucose infusion was significantly higher than baseline (18.57 ±0.38 [SEM] vs 17.54 ±0.25 mol%, P < .05). The 13C isotope ratio of plasma cysteine was also significantly higher than baseline (17.36 ±0.25 vs 16.91 ±0.16 mol%, P < .05)-. When expressed as a product/precursor ratio, the mole percent above baseline of [13C]apo B-100 cysteine/ [13C6]-glucose correlated with birth weight (r = 0.74, P < .01). Very low-birth weight neonates are capable of cysteine synthesis as evidenced by incorporation of 13C label into hepatically derived apo B-100 cysteine and plasma cysteine from a glucose precursor. The minimum capacity for intrahepatic cysteine synthesis appears to be directly proportional to the maturity of the neonate and may impact the capabilities of VLBW neonates to counteract oxidative stresses such as bronchopulmonary dysplasia and necrotizing enterocolitis.
